Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. [Eur Respir J] Journal article | | Title | Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. | | Author(s) | Martinez FJ, Grossman RF, Zadeikis N, Fisher AC, Walker K, Ambruzs ME, Tennenberg AM | | Institution | The University of Michigan Health System, 1500 East Medical Center Drive, 3916 Taubman Center, Box 0360, Ann Arbor, MI 48109, USA. fmartine@umich.edu | | Source | Eur Respir J 2005 Jun; 25(6):1001-10. | | MeSH | Administration, Oral
Adolescent
Adrenal Cortex Hormones
Adult
Aged
Amoxicillin-Potassium Clavulanate Combination
Anti-Bacterial Agents
Bronchitis, Chronic
Chronic Disease
Comparative Study
Cost-Benefit Analysis
Diarrhea
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Drug Therapy, Combination
Female
Haemophilus influenzae
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Nausea
Ofloxacin
Patient Selection
Research Support, Non-U.S. Gov't
Streptococcus pneumoniae
Treatment Outcome
| | Abstract | This is the first prospective clinical trial in which patients with acute bacterial exacerbation of chronic bronchitis have been stratified by degree of underlying illness. Uncomplicated patients were randomised to levofloxacin 750 mg once daily (q.d.) for 3 days or azithromycin q.d. for 5 days. Complicated patients were randomised to levofloxacin 750 mg q.d. for 5 days or amoxicillin 875 mg/clavulanate 125 mg twice daily for 10 days. Regardless of therapy, complicated patients demonstrated lower clinical and microbiological success than uncomplicated patients. Clinical success for clinically evaluable patients was similar for levofloxacin and azithromycin (93.0 versus 90.1%, respectively), and levofloxacin and amoxicillin/clavulanate (79.2 versus 81.7%, respectively). For microbiologically evaluable patients, clinical response to levofloxacin for 3 days was superior to azithromycin for 5 days (96.3 versus 87.4%, respectively), and levofloxacin for 5 days was similar to amoxicillin/clavulanate for 10 days (81.4 versus 80.9%, respectively). Microbiological eradication was superior for levofloxacin for 3 days compared with azithromycin for 5 days (93.8 versus 82.8%, respectively), and similar for levofloxacin and amoxicillin/clavulanate for 10 days (81.4 versus 79.8%, respectively). In conclusion, levofloxacin 750 mg for 3 days was comparable to azithromycin for 5 days for uncomplicated patients with acute bacterial exacerbation of chronic bronchitis, while 5 days of 750 mg levofloxacin was comparable to 10 days of amoxicillin/clavulanate for complicated acute bacterial exacerbation of chronic bronchitis. | | Language | eng | | Pub Type(s) | Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
| | PubMed ID | 15929954 |
|
|
| |
Advertise on this site.
| | |
|
